Citadel Advisors’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-55,700
| Closed | -$2.64M | – | 12553 |
|
|
2025
Q3 | $2.64M | Sell |
55,700
-63,700
| -53% | -$3.08M | ﹤0.01% | 5525 |
|
|
2025
Q2 | $6.37M | Buy |
119,400
+48,000
| +67% | +$2.18M | ﹤0.01% | 3709 |
|
|
2025
Q1 | $2.89M | Buy |
71,400
+50,700
| +245% | +$2.15M | ﹤0.01% | 4829 |
|
|
2024
Q4 | $576K | Sell |
20,700
-9,100
| -31% | -$276K | ﹤0.01% | 8250 |
|
|
2024
Q3 | $855K | Sell |
29,800
-17,200
| -37% | -$448K | ﹤0.01% | 7172 |
|
|
2024
Q2 | $1.1M | Sell |
47,000
-23,500
| -33% | -$503K | ﹤0.01% | 6389 |
|
|
2024
Q1 | $1.78M | Buy |
70,500
+16,200
| +30% | +$389K | ﹤0.01% | 5752 |
|
|
2023
Q4 | $1.27M | Buy |
54,300
+3,300
| +6% | +$65.1K | ﹤0.01% | 6220 |
|
|
2023
Q3 | $2.58M | Buy |
51,000
+26,600
| +109% | +$1.24M | ﹤0.01% | 4761 |
|
|
2023
Q2 | $1.14M | Sell |
24,400
-100
| -0.4% | -$4.58K | ﹤0.01% | 6186 |
|
|
2023
Q1 | $937K | Sell |
24,500
-23,000
| -48% | -$1.03M | ﹤0.01% | 6920 |
|
|
2022
Q4 | $2.6M | Sell |
47,500
-73,000
| -61% | -$3.13M | ﹤0.01% | 4997 |
|
|
2022
Q3 | $4.1M | Buy |
+120,500
| New | +$1.84M | ﹤0.01% | 4200 |
|
|
2021
Q4 | – | Sell |
-14,400
| Closed | -$322K | – | 13721 |
|
|
2021
Q3 | $322K | Sell |
14,400
-9,400
| -39% | -$213K | ﹤0.01% | 10900 |
|
|
2021
Q2 | $590K | Sell |
23,800
-24,500
| -51% | -$688K | ﹤0.01% | 9659 |
|
|
2021
Q1 | $1.4M | Buy |
48,300
+38,600
| +398% | +$1.17M | ﹤0.01% | 7279 |
|
|
2020
Q4 | $250K | Buy |
+9,700
| New | +$270K | ﹤0.01% | 9390 |
|
|
2020
Q3 | – | Sell |
-8,500
| Closed | -$212K | – | 10017 |
|
|
2020
Q2 | $212K | Buy |
+8,500
| New | +$194K | ﹤0.01% | 8444 |
|
Other funds holding AKRO
Citadel Advisors's AKRO Position: Q4 2025 in Review
Citadel Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 685,842 shares — an estimated $32.6M sold.
Citadel Advisors first reported a position in AKRO in Q3 2019 and held it in 24 quarters. The position peaked at $77.3M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Citadel Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 685,842 Akero Therapeutics shares in Q4 2025, an estimated $32.6M.
- Citadel Advisors first reported a position in Akero Therapeutics in Q3 2019 and held it in 24 quarters.
- Citadel Advisors's Akero Therapeutics position peaked at $77.3M in Q1 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.